| Recruiting | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma NCT07388563 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of NCT06947967 | Chipscreen Biosciences, Ltd. | Phase 3 |
| Recruiting | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Other NCT06561048 | Corvus Pharmaceuticals, Inc. | Phase 3 |
| Active Not Recruiting | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers NCT06254495 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Terminated | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers NCT06120504 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Suspended | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL NCT05138458 | Myeloid Therapeutics | Phase 1 / Phase 2 |
| Unknown | Brentuximab Vedotin in Combination With CHEP in Patient With PTCL NCT05006664 | Czech Lymphoma Study Group | Phase 2 |
| Completed | A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Ce NCT05137847 | Eisai Inc. | — |
| Terminated | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders NCT03601819 | University of Michigan Rogel Cancer Center | Phase 1 |
| Completed | ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma NCT03742921 | Celgene | — |
| Active Not Recruiting | Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) NCT03547700 | Ryan Wilcox | Phase 1 / Phase 2 |
| Withdrawn | Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL NCT03355768 | Jennifer Amengual | Phase 3 |
| Completed | Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma NCT03302728 | Peter MacCallum Cancer Centre, Australia | Phase 1 |
| Completed | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas NCT03049449 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Ly NCT03051568 | Peking University Cancer Hospital & Institute | N/A |
| Unknown | 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma NCT03051581 | Peking University Cancer Hospital & Institute | N/A |
| Terminated | Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin L NCT02535247 | Fox Chase Cancer Center | Phase 1 / Phase 2 |
| Completed | A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas NCT02788916 | Takeda | — |
| Completed | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma NCT02567656 | Rhizen Pharmaceuticals SA | Phase 1 |
| Terminated | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685 | Asana BioSciences | Phase 1 / Phase 2 |
| Completed | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory NCT02181218 | Washington University School of Medicine | Phase 1 |
| Unknown | Cohort of Peripheral T Cell Lymphoma NCT02364466 | Korea Cancer Center Hospital | — |
| Completed | A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With NCT01456039 | Celgene | Phase 1 / Phase 2 |
| Unknown | GDP in Frontline Chemotherapy for Patients With PTCL-NOS NCT02404571 | Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease NCT01155817 | Stanford University | Phase 1 |
| Completed | Alemtuzumab and CHOP in T-cell Lymphoma NCT00646854 | Aarhus University Hospital | Phase 3 |
| Completed | Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma NCT01679860 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Completed | T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma NCT01142674 | Associazione Angela Serra per la ricerca sul cancro | — |
| Completed | A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma NCT00211185 | Eisai Inc. | Phase 2 |
| Terminated | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies NCT00514722 | University of California, San Francisco | N/A |